Eli Lilly (NYSE:LLY) shares edged 0.9% lower in premarket trading on Thursday after the U.S. Food and Drug Administration postponed its decision on the company’s weight-loss pill until April 10.
The FDA had previously been expected to issue a ruling by late March, raising uncertainty around the approval timeline for the treatment.
The drug had been included in the agency’s fast-track review program, which is designed to deliver decisions within one to two months for a select group of therapies deemed important to public health or national security.
More about Eli Lilly
Eli Lilly is a global pharmaceutical company focused on developing medicines across areas including diabetes, obesity, oncology, immunology, and neuroscience. The company has been expanding its portfolio of metabolic disease treatments amid strong demand for weight-loss and diabetes therapies.